Nicotinic acetylcholine receptor alpha-3 beta-2 subtype (alpha3beta2 nAChR)

The Nicotinic acetylcholine receptor alpha-3 beta-2 (alpha3beta2) subtype is a pentameric ligand-gated ion channel primarily expressed in the peripheral nervous system, particularly in autonomic ganglia, and specific regions of the central nervous system [UniProt, PubMed]. It is composed of alpha-3 and beta-2 subunits that assemble to form a cation-selective pore, which opens in response to the binding of the endogenous neurotransmitter acetylcholine [UniProt, IUPHAR/BPS]. This receptor subtype plays a vital role in mediating fast excitatory synaptic transmission and modulating the release of other neurotransmitters such as dopamine and norepinephrine [PubMed]. In clinical contexts, alpha3beta2 receptors are heavily implicated in the mechanisms of nicotine addiction and have been associated with genetic susceptibility to lung cancer and chronic obstructive pulmonary disease [NIH, PubMed]. They also represent potential therapeutic targets for treating autonomic nervous system dysfunctions and certain neurodegenerative conditions [PubMed]. Pharmacological agents interacting with this receptor include non-selective agonists like nicotine and varenicline, as well as highly selective antagonists like alpha-conotoxin MII [PubChem, PubMed]. A significant challenge in targeting the alpha3beta2 subtype is achieving selectivity over other closely related nicotinic receptors, such as the alpha4beta2 and alpha3beta4 subtypes [DrugBank, PubMed]. Off-target activation or inhibition can lead to adverse effects, particularly within the cardiovascular and gastrointestinal systems, where other nicotinic subtypes predominate [DrugBank].

Other names

CHRNA3/CHRNB2 receptorNeuronal nicotinic acetylcholine receptor alpha-3 beta-2alpha3beta2 nicotinic receptoralpha3beta2 nAChR

Agonist or antagonist binding to the extracellular domain induces a conformational change that opens or blocks a cation-selective transmembrane pore, modulating cellular excitability and neurotransmitter release [UniProt, PubMed].